US pharmaceutical company Pfizer Inc (NYSE:PFE) said on Tuesday it will allow generic manufacturers to supply its experimental antiviral COVID-19 pill to 95 low-income and middle-income countries through a licensing agreement with UN backed, international public health group Medicines Patent Pool (MPP), Reuters news agency reported on Wednesday.
This voluntary licensing agreement will allow MPP to grant sub-licences to qualified generic drug manufacturers to make their own versions of the Pfizer drug, PF-07321332.
Pfizer will sell the pills it manufactures under the brand name Paxlovid.
The 95 countries in the agreement reportedly cover around 53% of the world's population and include all low-income and lower-middle-income countries and some upper-middle-income countries in Sub-Saharan Africa.
It also includes countries that have transitioned from lower-middle to upper-middle-income status in the past five years, Pfizer and the MPP said.
According to Pfizer, it will waive royalties on sales in low-income countries and also waive them in the other countries covered by the agreement, as long as COVID-19 remains classified as a public health emergency of international concern by the World Health Organisation.
Pfizer expects to manufacture 180,000 treatment courses by the end of next month and at least 50 million courses by the end of 2022.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US